Blood CancersNCT07714044
Rutgers University Study of the Genetics of Blood Cancers
An observational study of Blood Cancers and Blood Cancer, run by Rutgers, The State University of New Jersey at 1 site in United States.
Trial summary
The goal of this study is to enroll at least 10,000 participants nationally including affecteds and unaffecteds via online study portal, collect surveys online and a saliva sample through the mail, sequence DNA, and conduct genetic analyses to identify novel variants and further study known variants associated with… Read more about this study
- Who is it for?
- Ages 18 to 110 yearsHealthy volunteers can take part
- Conditions the study is for
- Blood Cancers, Blood Cancer, Leukemia
- How many people
- 10,000 participants
- Where
- 1 siteUnited States
- Study dates
- 22 Sep 2026to Aug 2029
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 110 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: The study population consists of anyone at least 18 years old who lives in the United States, including both individuals who have or had blood cancer and those who have not. Participants include males, females, non-binary, and all race-ethnic groups.
Who may be able to join
- age 18 years or older
- currently living in the United States
- have access to the internet and a computer, laptop, tablet or smartphone
- willing to provide written informed consent for participation
- willing to provide DNA via a saliva sample using a collection kit mailed to your home
- willing to complete a survey with questions about health related to the study of blood cancer.
Who cannot join
- Not able to meet or fulfill any of the inclusion criteria
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
Rutgers University
Piscataway, New Jersey, 08854
Tara Matise, PhD, 848-445-3125, rugcc@rutgers.edu
Tara Matise, PhD
About this study
Official title: The Rutgers University Study of the Genetics of Blood Cancers
The goal of this study is to enroll at least 10,000 participants nationally including affecteds and unaffecteds via online study portal, collect surveys online and a saliva sample through the mail, sequence DNA, and conduct genetic analyses to identify novel variants and further study known variants associated with leukemia, lymphoma, myeloma and other blood cancers.
Read the detailed description
This is an online research study to learn more about how genes affect your risk of blood cancers. No office visit is required and in return, participants may receive information about their genetic ancestry for free. This study will increase our understanding of the genetic basis of blood cancers, which is a crucial step in drug development to improve current treatment options. We seek a diverse population because diversity among participants maximizes the usefulness of the data. Participants will use our online study portal to answer questions about their health and provide their DNA via a saliva sample using a pre-paid mailer. Participation takes approximately 20 minutes. Participants will be invited to share data from their electronic health records, but this is not required for study participation. We keep participants engaged with short monthly newsletters.
- Conditions
- Blood Cancers, Blood Cancer, Leukemia, Lymphoma, Myeloma, Hematologic Cancer
- Keywords
- genetics, blood cancer, blood cancers, leukemia, lymphoma, myeloma, hematologic cancer, hematologic malignancy, hematologic tumor, hematologic neoplasm
- Medical subject headings
- Hematologic Neoplasms, Leukemia, Lymphoma, Neoplasms, Plasma Cell
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Cases | Persons with blood cancer | |
| Controls | Persons who do not have blood cancer |
What is being measured
The primary outcome is the main question the study is designed to answer.
Genetic risk variants associated with blood cancer
Genetic factors will be measured through whole exome sequencing and genome-wide genotyping array, and then correlated with blood cancer subtype.
Measured: 2 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Jul 2026
- Study start22 Sep 2026
- Primary completionAug 2029 (estimated)
- Study completionAug 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Blood CancersStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Enrolment
- 10,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Rutgers, The State University of New Jersey
- Sponsor type
- University, hospital or other
- Collaborators
- Regeneron Pharmaceuticals
- Responsible party
- Principal investigator, Tara Matise, Ph.D., Rutgers, The State University of New Jersey
- Investigators
- Tara Matise, PhD, Principal investigator, Rutgers University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07714044
- Sponsor's protocol ID
- Pro2026000226
- Status last verified
- Sep 2026
- First submitted
- 15 Jul 2026
- Last updated
- 1 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Our study protocol does not include sharing IPD.